RVO
HomeMarketplace
Register
Register
Register

daniel lüscher

CEO

QBDC GmbH

Nusshof, Switzerland

Swiss participant Biotech

QBDC consults on biomanufacturing CMC, qualification, and bioprocessing. We develop digital tools ML tools for faster and compliant drug development

My organisation

QBDC GmbH

QBDC GmbH

Consultant

4453 Nusshof, Switzerland

QBDC GmbH, with locations in Switzerland and Austria, is a biopharmaceutical consultancy firm dedicated to optimizing biomanufacturing processes and providing innovative solutions for the industry. Their core mission revolves around making biopharmaceuticals more affordable and accessible by enhancing efficiency and compliance throughout the drug development lifecycle. Here's a breakdown of QBDC's key activities and expertise: 1. CMC Development Consulting (Chemistry, Manufacturing, and Controls): Regulatory Compliance: QBDC ensures that biopharmaceutical products and processes adhere to stringent regulatory standards (e.g., GMP - Good Manufacturing Practices) set by authorities like the FDA and EMA., Process Optimization: They work to streamline and improve manufacturing processes, aiming to reduce costs, enhance product quality, and increase efficiency. This includes everything from DNA to market entry., Product Development: QBDC supports clients in developing high-quality, safe, and effective biopharmaceutical products, particularly focusing on biologics such as Biosimilars, ATMPs (Advanced Therapy Medicinal Products), and NBEs (New Biological Entities)., Scale-up and Tech Transfer: They provide expertise in scaling up manufacturing processes and facilitating technology transfer between different sites or partners., QC/QA Support: QBDC offers support in Quality Control and Quality Assurance, critical for ensuring product consistency and safety. 2. Qualification & Validation: Document Creation: They assist in creating comprehensive documentation necessary for regulatory compliance., Risk-Based Project Management: QBDC employs risk-based approaches to project management, enhancing quality and safety throughout the development process., GMP Upgrades: They help companies upgrade their facilities to meet evolving GMP regulations and adapt to changes in product requirements., Accuracy and Efficiency: Their focus in this area is on guaranteeing accuracy, efficiency, and regulatory compliance in all qualification and validation activities. 3. Bioprocessing & PAT (Process Analytical Technology): Bioprocess Streamlining: QBDC helps clients streamline their bioprocesses to reduce costs and improve overall quality., EDDI (Epigenetic Digital Data Interface): A key innovation from QBDC, EDDI is a proprietary digital tool that provides real-time insights into cellular behavior by monitoring gene activation and epigenetic data. This allows for precise cell characterization, eliminates guesswork, and enables informed decisions in bioprocess optimization. EDDI helps in identifying optimal "working conditions" for enhanced cell productivity, revolutionizing biopharmaceutical development by "listening" to cells and translating their signals into actionable digital data., Digital Twins: QBDC is working on fusing biochemical pathways and epigenetic data with machine learning (ML) and artificial intelligence (AI) to create digital twins, aiming to further revolutionize the pharmaceutical industry. 4. Digital Tools and Solutions: Beyond consulting, QBDC develops affordable software products to address everyday documentation and data management challenges in biopharma. These include: METIS: A solution for managing experimental data., Validated Document Management Systems: Affordable and GMP-compliant systems like TEMIS, designed for secure and efficient organization of critical documents and media, particularly valuable for startups, SMEs, and even sections of larger companies. TEMIS focuses on data integrity, audit trails, and multi-user capabilities within a GMP environment.
Read more

About me

Skills

  • Bioprocess
  • biotechnology
  • epigenetics
  • Lifecycle Management
  • CMC Development

Marketplace (3)

  • Service

    CMC Consulting

    QBDC optimizes biopharma CMC, ensuring regulatory compliance, efficient development, and robust manufacturing for high-quality, safe drugs.

    • Consulting
    • Development
    • Innovative therapies - Gene therapy
    • Innovative therapies - Stem cell therapy
    • Innovative therapies - Oncolytic viruses
    • Innovative therapies - Immune cell therapy
    • Innovative therapies - Somatic cell therapy
    • Development stages and support fuctions - Data management and analytics
    • Development stages and support fuctions - Contract research (CRO / CRMO)
    • Development stages and support fuctions - Clinical research and development
    • Development stages and support fuctions - Development and (GMP) manufacturing
    • Development stages and support fuctions - Pre-clinical research and development
    • Development stages and support fuctions - Commercial strategy and market access
    Author

    daniel lüscher

    CEO at QBDC GmbH

    Nusshof, Switzerland

  • Service

    Qualification & Validation Services

    QBDC consults on Biopharma Qualification & Validation for GMP-compliant processes, documentation, and upgrades.

    • Consulting
    • Manufacturing
    • Development stages and support fuctions - Data management and analytics
    • Development stages and support fuctions - Development and (GMP) manufacturing
    Author

    daniel lüscher

    CEO at QBDC GmbH

    Nusshof, Switzerland

  • Product

    EDDI - Epigenetic Digital Data Interface

    EDDI is providing real-time cell insights to optimize bioprocessing and enhance drug development efficiency.

    • Innovative therapies - RNA therapy
    • Innovative therapies - Gene therapy
    • Innovative therapies - Gene editing
    • Innovative therapies - Nanomedicine
    • Innovative therapies - Stem cell therapy
    • Innovative therapies - Oncolytic viruses
    • Innovative therapies - Microbiome therapy
    • Innovative therapies - Precision medicine
    • Innovative therapies - Immune cell therapy
    • Innovative therapies - Somatic cell therapy
    • Innovative therapies - Tissue engineered products
    • Innovative human-based test models - 3D spheroids
    • Innovative human-based test models - 3D spheroids
    • Innovative human-based test models - Organ-on-Chip
    • Innovative human-based test models - In silico human models
    • Development stages and support fuctions - Regulatory and compliance
    • Innovative human-based test models - Bioprinted tissues and constructs
    • Development stages and support fuctions - Data management and analytics
    • Innovative human-based test models - Assembloids and multi-tissue models
    • Development stages and support fuctions - Contract research (CRO / CRMO)
    • Innovative human-based test models - 2D & 3D in vitro cell culture models
    • Development stages and support fuctions - Early discovery / basic research
    • Development stages and support fuctions - Funding, capital and investments
    • Development stages and support fuctions - Ethics and social responsibility
    • Development stages and support fuctions - Clinical research and development
    • Development stages and support fuctions - Development and (GMP) manufacturing
    • Development stages and support fuctions - Technology development and validation
    • Development stages and support fuctions - Pre-clinical research and development
    • Development stages and support fuctions - Commercial strategy and market access
    Author

    daniel lüscher

    CEO at QBDC GmbH

    Nusshof, Switzerland